Corbus Pharmaceuticals Holdings (LTS:0SZI) Other Current Receivables: $0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0SZI Corbus Pharmaceuticals Holdings Inc LTS:0SZI
44 GF Score
Price $9.93
GF Value $1.01
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Corbus Pharmaceuticals Holdings Other Current Receivables?

Corbus Pharmaceuticals Holdings LTS:0SZI +3.03% 44 Other Current Receivables is $0.00 Mil as of Jun. 2026. GuruFocus rates LTS:0SZI with a GF Score™ of 44/100 and a GF Value™ of $1.01 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Corbus Pharmaceuticals Holdings's Other Current Receivables for the quarter that ended in Jun. 2026 was $0.00 Mil.

Corbus Pharmaceuticals Holdings Other Current Receivables Related Terms

Corbus Pharmaceuticals Holdings Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Corbus Pharmaceuticals Holdings's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Corbus Pharmaceuticals Holdings Other Current Receivables Chart

Corbus Pharmaceuticals Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Corbus Pharmaceuticals Holdings Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
LTS:0SZI
44GF Score
Corbus Pharmaceuticals Holdings Inc LTS:0SZI
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Corbus Pharmaceuticals Holdings Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of $0.00 Mil mean?
Corbus Pharmaceuticals Holdings (LTS:0SZI) has a Other Current Receivables of $0.00 Mil as of Jun. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Corbus Pharmaceuticals Holdings and its competitors.
Is Corbus Pharmaceuticals Holdings' Other Current Receivables too high?
Corbus Pharmaceuticals Holdings' current Other Current Receivables is $0.00 Mil. Overall, Corbus Pharmaceuticals Holdings has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Corbus Pharmaceuticals Holdings' Other Current Receivables compare to OKUR and HUMA?
Corbus Pharmaceuticals Holdings' Other Current Receivables of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Biotechnology company?
A good Other Current Receivables depends on the Biotechnology industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Corbus Pharmaceuticals Holdings and its competitors. Corbus Pharmaceuticals Holdings's current Other Current Receivables is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corbus Pharmaceuticals Holdings stock overvalued right now?
Based on GuruFocus' analysis, Corbus Pharmaceuticals Holdings (LTS:0SZI) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.01, compared to a current price of $9.93 — trading 883.4% above its estimated fair value. The current Other Current Receivables is $0.00 Mil. Corbus Pharmaceuticals Holdings' overall GF Score™ is 44/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Corbus Pharmaceuticals Holdings (LTS:0SZI), the current Other Current Receivables is $0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Corbus Pharmaceuticals Holdings (LTS:0SZI) Overvalued in 2026?

Based on GuruFocus' analysis, Corbus Pharmaceuticals Holdings stock appears to be overvalued. The current stock price of $9.93 is trading 883.4% above its estimated GF Value™ of $1.01. GuruFocus considers Corbus Pharmaceuticals Holdings to be Significantly Overvalued.

Key valuation signals for LTS:0SZI:

  • Other Current Receivables: $0.00 Mil
  • GF Value™: $1.01 vs. price of $9.93 (883.4% above fair value)
  • GF Score™: 44/100 with 2 warning signs

No single metric tells the full story. See the LTS:0SZI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Corbus Pharmaceuticals Holdings Business Description

Other Exchanges CRBP:USA3371:Germany
Address 500 River Ridge Drive, Norwood, MA, USA, 02062
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
44GF Score

Get the complete analysis for LTS:0SZI

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.93
Price
$1.01
GF Value